Meissner to build new $250m manufacturing facility in Athens, Georgia
The project will more than double the company’s manufacturing footprint in the US, and is expected to create more than 1,700 new jobs over the next eight years.
Second US manufacturing site
Meissner is one of the world’s largest privately held companies in the bioprocessing sector: developing, manufacturing, supplying and servicing products and systems for the pharmaceutical and biopharmaceutical industries.
Its current manufacturing campuses are its headquarters location in Camarillo, California; and a European manufacturing location in Castlebar, Ireland.
“We are thrilled to embark on this important expansion and are excited to build our second US manufacturing campus in Athens-Clarke County,” said Christopher Meissner, President of Meissner. “The State of Georgia, and Athens-Clarke County in particular, is an ideal location with an incredible talent pool and strong geographic position that allows us to serve clients on the East Coast and throughout the world.”
Meissner’s new facility will be located at the Christian Industrial Tract, located at 1310 Spring Valley Road, in Winterville. When the currently planned phases are complete, the new campus will more than double the company’s manufacturing footprint in the US as the company expands its current operations.
Meissner expects the new site in Athens-Clarke County to consist of multiple structures, which will include state-of-the-art cleanroom facilities, laboratories, research and development, and office spaces.
Operations are due to begin in early 2026.
Meissner will recruit a broad range of roles including technicians, scientists and engineers, as well as information technology and administrative positions. The company also pledges to work with the University System of Georgia and the Technical College System of Georgia, including schools such as the University of Georgia, Georgia Institute of Technology, and Athens Technical College. These partnerships will explore potential internship and other collaboration opportunities through relevant programs of study.
Founded in 1984 and headquartered in Camarillo, California, Meissner operations globally which a product portfolio that enables the development and manufacture of critical medicines in therapeutic areas such as oncology, cardiology and immunology.
It manufactures advanced microfiltration products and therapeutic manufacturing systems for both pharmaceutical and biopharmaceutical applications, such as sterilization of injectable drugs, and the development and manufacture of life-enhancing/life-saving drugs, therapeutics, biologics, and cell and gene therapies. The company is a supplier to manufacturers of COVID-19 vaccines, therapies, treatments, and associated test kits.
